We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI-Powered Cardiac Device Identifies Potential Heart Issues Before They Become Life-Threatening

By HospiMedica International staff writers
Posted on 15 Sep 2023

Nearly one-third of all heart attacks show no symptoms, and for over half of the people who suffer from cardiac-related fatalities, the first warning sign is the heart attack itself. More...

Unfortunately, most individuals don't seek medical help until they notice symptoms or actually experience a heart attack. Now, the world’s first early detection device for heart disease and other underlying cardiac issues is poised to revolutionize the field of cardiovascular care.

Forum Health (Flint, MI, USA) has rolled out its Multifunction Cardiogram (MCG) scan aimed at the early detection of heart disease and cardiac abnormalities. Designed as a preventive tool, the MCG scan is intended for both young and general populations who face an increased risk of heart disease. In contrast to traditional diagnostic approaches that wait for symptoms to appear, the MCG scan leverages cutting-edge artificial intelligence (AI) to identify a broad spectrum of heart-related issues. The system becomes more intelligent with each scan, making it the most thorough and precise heart assessment tool currently available.

Taking an MCG test is as simple as undergoing a 10-minute resting EKG, requiring no preparation from the patient. All the individual needs to do is lie still and relax while the device scans and gathers data about their heart. Specifically, the MCG evaluates how effectively blood is circulating into and out of the heart, as well as the overall health of the heart muscle. This collected data is then sent to a server where it's compared against a database featuring 200,000 patients with confirmed cardiovascular disease, as validated by angiograms. The MCG algorithm then gauges the patient's data against these established cases and produces an objective score ranging from 0 to 22 to measure heart dysfunction—the lower the score, the better the heart's condition. A detailed diagnostic report is then generated and shared securely with the attending physician. This report outlines whether the patient shows signs of local ischemia, global ischemia, or both, along with 26 other indicators of possible disease and inflammation.

"The MCG scan is a revolutionary cardiac device,” said Dr. Steven Meress, Forum Health Fond du Lac. “In March 2023, we performed the first round of scans; five months later, 12 out of 12 follow-up scans show improvement. This evidence shows how effective early interventions can be when based off the MCG scan and the positive impact on cardiac health."

Related Links:
Forum Health 


Gold Member
Blood Gas Analyzer
i-Check200
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Rapid Sepsis Test
SeptiCyte RAPID
Digital Radiography System (Ceiling Free)
Digix CF Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Medical Imaging

view channel
Image: Annotation platform for pixel-level labeling of free-text findings in 3D chest CT. (Baharoon M, Luo L, Moritz M, et al. ReXGroundingCT: A 3D chest CT dataset for segmentation of findings from free-text reports. NEJM AI. 2026;3(7). doi:10.1056/AIdbp2501220.)

Public Chest CT Dataset Supports Explainable AI in Diagnostic Radiology

Chest computed tomography scans generate complex three-dimensional images that can be difficult for artificial intelligence systems to explain clearly. Clinicians need to verify AI findings before using... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: The proposed acquisition would add NeoCast, an investigational next-generation liquid embolic technology for chronic subdural hematoma (cSDH), to Terumo Neuro’s neurovascular portfolio. (Photo courtesy of Arsenal Medical)

Terumo Neuro Acquisition Advances Liquid Embolic Technology for Chronic Subdural Hematoma

Terumo Neuro (Aliso Viejo, CA, USA) signed an agreement to acquire Arsenal Medical Inc. (Waltham, MA, USA), a privately held, clinical-stage biomaterials company. The proposed acquisition would add NeoCast,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.